AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXR
  4. [Form 4] Daxor Corporation Insider Trading Activity

[Form 4] Daxor Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Daxor (DXR) filed a routine Form 4 disclosing that director Henry D. Cremisi received an option grant for 2,500 common-stock shares on June 24 2025 under the company鈥檚 2020 Incentive Compensation Plan, contingent upon SEC approval of an amendment to that plan. The options carry a $9.29 exercise price and vest in three annual tranches (833/883/834 shares through 2027). No DXR shares were bought or sold, and Cremisi鈥檚 beneficial ownership now includes the new grant. The filing does not report any other transactions or material changes.

Daxor (DXR) ha presentato un modulo di routine Form 4, comunicando che il direttore Henry D. Cremisi ha ricevuto una concessione di opzioni per 2.500 azioni ordinarie il 24 giugno 2025 nell鈥檃mbito del Piano di Incentivazione 2020 della societ脿, subordinata all鈥檃pprovazione da parte della SEC di una modifica a tale piano. Le opzioni hanno un prezzo di esercizio di 9,29 USD e maturano in tre tranche annuali (833/883/834 azioni fino al 2027). Non sono state acquistate o vendute azioni DXR, e la propriet脿 effettiva di Cremisi ora include la nuova concessione. La comunicazione non riporta altre transazioni o cambiamenti significativi.

Daxor (DXR) present贸 un Formulario 4 rutinario informando que el director Henry D. Cremisi recibi贸 una concesi贸n de opciones para 2,500 acciones comunes el 24 de junio de 2025 bajo el Plan de Compensaci贸n por Incentivos 2020 de la compa帽铆a, condicionado a la aprobaci贸n de una enmienda a dicho plan por parte de la SEC. Las opciones tienen un precio de ejercicio de 9,29 USD y se consolidan en tres tramos anuales (833/883/834 acciones hasta 2027). No se compraron ni vendieron acciones de DXR, y la propiedad beneficiaria de Cremisi ahora incluye la nueva concesi贸n. La presentaci贸n no reporta otras transacciones ni cambios materiales.

Daxor (DXR)電� 鞚挫偓 項Μ D. 韥爤氙胳嫓臧� 須岇偓鞚� 2020 鞚胳劶韹半笇 氤挫儊 瓿勴殟鞐� 霐半澕 2025雲� 6鞗� 24鞚检棎 2,500 氤错喌欤� 鞓奠厴 攵�鞐�毳� 氚涭晿鞚岇潉 鞎岆Μ電� 鞝曣赴 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞚措姅 SEC鞚� 頃措嫻 瓿勴殟 靾橃爼 鞀轨澑鞐� 霐半ジ 臁瓣贝攵�鞛呺媹雼�. 鞓奠厴 頄夓偓臧�瓴╈潃 9.29雼煬鞚措┌ 3雲勳棎 瓯胳硱 鞐瓣皠 攵勴暊(833/883/834欤�, 2027雲勱箤歆�)搿� 甓岆Μ臧� 氚滌儩頃╇媹雼�. DXR 欤检嫕鞚� 毵るГ電� 鞐嗢棃鞙茧┌, 韥爤氙胳嫓鞚� 鞁れ 靻岇湢甓岇棎電� 鞚措矆 鞁犼窚 攵�鞐秳鞚� 韽暔霅╇媹雼�. 鞝滌稖靹滊鞐愲姅 雼るジ 瓯半灅雮� 欷戩殧頃� 氤�瓴� 靷暛鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Daxor (DXR) a d茅pos茅 un formulaire 4 de routine indiquant que le directeur Henry D. Cremisi a re莽u une attribution d鈥檕ptions pour 2 500 actions ordinaires le 24 juin 2025 dans le cadre du Plan de R茅mun茅ration Incitative 2020 de la soci茅t茅, sous r茅serve de l鈥檃pprobation par la SEC d鈥檜n amendement 脿 ce plan. Les options ont un prix d鈥檈xercice de 9,29 $ et se d茅bloquent en trois tranches annuelles (833/883/834 actions jusqu鈥檈n 2027). Aucune action DXR n鈥檃 茅t茅 achet茅e ou vendue, et la propri茅t茅 b茅n茅ficiaire de Cremisi inclut d茅sormais cette nouvelle attribution. Le d茅p么t ne signale aucune autre transaction ni changement significatif.

Daxor (DXR) reichte routinem盲脽ig ein Formular 4 ein und gab bekannt, dass Direktor Henry D. Cremisi am 24. Juni 2025 eine Optionszuteilung 眉ber 2.500 Stammaktien im Rahmen des Incentive Compensation Plans 2020 des Unternehmens erhalten hat, vorbehaltlich der Genehmigung einer Plan盲nderung durch die SEC. Die Optionen haben einen Aus眉bungspreis von 9,29 USD und werden in drei j盲hrlichen Tranchen (833/883/834 Aktien bis 2027) erworben. Es wurden keine DXR-Aktien gekauft oder verkauft, und Cremisis wirtschaftliches Eigentum umfasst nun die neue Zuteilung. Die Einreichung meldet keine weiteren Transaktionen oder wesentlichen 脛nderungen.

Positive
  • None.
Negative
  • None.

Daxor (DXR) ha presentato un modulo di routine Form 4, comunicando che il direttore Henry D. Cremisi ha ricevuto una concessione di opzioni per 2.500 azioni ordinarie il 24 giugno 2025 nell鈥檃mbito del Piano di Incentivazione 2020 della societ脿, subordinata all鈥檃pprovazione da parte della SEC di una modifica a tale piano. Le opzioni hanno un prezzo di esercizio di 9,29 USD e maturano in tre tranche annuali (833/883/834 azioni fino al 2027). Non sono state acquistate o vendute azioni DXR, e la propriet脿 effettiva di Cremisi ora include la nuova concessione. La comunicazione non riporta altre transazioni o cambiamenti significativi.

Daxor (DXR) present贸 un Formulario 4 rutinario informando que el director Henry D. Cremisi recibi贸 una concesi贸n de opciones para 2,500 acciones comunes el 24 de junio de 2025 bajo el Plan de Compensaci贸n por Incentivos 2020 de la compa帽铆a, condicionado a la aprobaci贸n de una enmienda a dicho plan por parte de la SEC. Las opciones tienen un precio de ejercicio de 9,29 USD y se consolidan en tres tramos anuales (833/883/834 acciones hasta 2027). No se compraron ni vendieron acciones de DXR, y la propiedad beneficiaria de Cremisi ahora incluye la nueva concesi贸n. La presentaci贸n no reporta otras transacciones ni cambios materiales.

Daxor (DXR)電� 鞚挫偓 項Μ D. 韥爤氙胳嫓臧� 須岇偓鞚� 2020 鞚胳劶韹半笇 氤挫儊 瓿勴殟鞐� 霐半澕 2025雲� 6鞗� 24鞚检棎 2,500 氤错喌欤� 鞓奠厴 攵�鞐�毳� 氚涭晿鞚岇潉 鞎岆Μ電� 鞝曣赴 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞚措姅 SEC鞚� 頃措嫻 瓿勴殟 靾橃爼 鞀轨澑鞐� 霐半ジ 臁瓣贝攵�鞛呺媹雼�. 鞓奠厴 頄夓偓臧�瓴╈潃 9.29雼煬鞚措┌ 3雲勳棎 瓯胳硱 鞐瓣皠 攵勴暊(833/883/834欤�, 2027雲勱箤歆�)搿� 甓岆Μ臧� 氚滌儩頃╇媹雼�. DXR 欤检嫕鞚� 毵るГ電� 鞐嗢棃鞙茧┌, 韥爤氙胳嫓鞚� 鞁れ 靻岇湢甓岇棎電� 鞚措矆 鞁犼窚 攵�鞐秳鞚� 韽暔霅╇媹雼�. 鞝滌稖靹滊鞐愲姅 雼るジ 瓯半灅雮� 欷戩殧頃� 氤�瓴� 靷暛鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Daxor (DXR) a d茅pos茅 un formulaire 4 de routine indiquant que le directeur Henry D. Cremisi a re莽u une attribution d鈥檕ptions pour 2 500 actions ordinaires le 24 juin 2025 dans le cadre du Plan de R茅mun茅ration Incitative 2020 de la soci茅t茅, sous r茅serve de l鈥檃pprobation par la SEC d鈥檜n amendement 脿 ce plan. Les options ont un prix d鈥檈xercice de 9,29 $ et se d茅bloquent en trois tranches annuelles (833/883/834 actions jusqu鈥檈n 2027). Aucune action DXR n鈥檃 茅t茅 achet茅e ou vendue, et la propri茅t茅 b茅n茅ficiaire de Cremisi inclut d茅sormais cette nouvelle attribution. Le d茅p么t ne signale aucune autre transaction ni changement significatif.

Daxor (DXR) reichte routinem盲脽ig ein Formular 4 ein und gab bekannt, dass Direktor Henry D. Cremisi am 24. Juni 2025 eine Optionszuteilung 眉ber 2.500 Stammaktien im Rahmen des Incentive Compensation Plans 2020 des Unternehmens erhalten hat, vorbehaltlich der Genehmigung einer Plan盲nderung durch die SEC. Die Optionen haben einen Aus眉bungspreis von 9,29 USD und werden in drei j盲hrlichen Tranchen (833/883/834 Aktien bis 2027) erworben. Es wurden keine DXR-Aktien gekauft oder verkauft, und Cremisis wirtschaftliches Eigentum umfasst nun die neue Zuteilung. Die Einreichung meldet keine weiteren Transaktionen oder wesentlichen 脛nderungen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cremisi Henry D.
(Last) (First) (Middle)
109 MECO LANE
(Street)
OAK RIDGE, TN 37830
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy) $9.29 06/24/2025(1) A 2,500 (2) 06/24/2030 COMMON STOCK 2,500 $0 2,500 D
Explanation of Responses:
1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
2. The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834)
/s/ Henry Cremisi 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider transaction did DXR report on June 29 2025?

DXR disclosed that director Henry D. Cremisi was granted 2,500 stock options at a $9.29 exercise price on June 24 2025.

Were any DXR shares bought or sold in this Form 4 filing?

No. The Form 4 only reports an option grant; no common shares were purchased or sold.
Stock DXR logo
DAXOR CORP

NASDAQ:DXR

DXR Rankings

#7933 Ranked by Market Cap
N/A Ranked by Dividends

DXR Latest News

Aug 12, 2025
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Aug 7, 2025
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Jul 22, 2025
Daxor鈥檚 Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
May 14, 2025
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
May 13, 2025
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

DXR Latest SEC Filings

Aug 7, 2025
[8-K] Daxor Corporation Reports Material Event
Jul 24, 2025
[N-CEN/A] Daxor Corporation SEC Filing
Jul 24, 2025
[N-CEN/A] Daxor Corporation SEC Filing
Jul 1, 2025
[8-K] Daxor Corporation Reports Material Event
Jun 26, 2025
[Form 4] Daxor Corporation Insider Trading Activity

DXR Stock Data

49.62M
2.14M
56.9%
1.96%
0.22%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
United States
NEW YORK